Overview

A HR20031 BE Study on Healthy Subjects

Status:
Not yet recruiting

Trial end date:
2024-05-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the bioequivalence between HR20031 FDC tablet and co-administration of SHR3824 tablets, SP2086 tablets and metformin XR tablets.

Phase:

Phase 1

Details

Lead Sponsor:

Shandong Suncadia Medicine Co., Ltd.